Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1945741Generated: October 25, 2026

4-(2-Methoxypropan-2-yl)piperidine → 4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine

https://huagongshe.com/reaction/1945741

Reaction equation

Participants

RoleNameHCIDCharge
Reactant4-(2-Methoxypropan-2-yl)piperidineHCID 59352871—
Reactant4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholineHCID 59603481—
Product4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholineHCID 5960572698.3%

Reaction Steps

4-(2-methoxypropan-2-yl)piperidine (0.12 g) was reacted with 4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (0.25 g) via General Procedure E to give 300 mg of crude 4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine, of which 0.78 g was reacted with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine via General Procedure A to yield 12 mg of 155 as a white solid following reverse phase purification. MS (Q1) 531.3 (M)+

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS08394796B2
Source datasetuspto-grants-2013_03
ORD IDord-1f50f778be924ae89a7bb8bc69569e74
Source noteuspto-grants-2013_03